Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -42.24% | -33.82% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -42.24% | -33.82% | |||
| Cost of Revenue | -60.34% | -48.00% | |||
| Gross Profit | -7.86% | 36.59% | |||
| SG&A Expenses | -45.15% | 92.95% | |||
| Depreciation & Amortization | -1.74% | 1.77% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -45.69% | 52.86% | |||
| Operating Income | 46.23% | -93.43% | |||
| Income Before Tax | 3,105.69% | 40.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2,703.52% | 40.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3,013.40% | 40.21% | |||
| EBIT | 46.23% | -93.43% | |||
| EBITDA | 47.27% | -97.61% | |||
| EPS Basic | 3,077.78% | 41.94% | |||
| Normalized Basic EPS | 73.33% | 77.27% | |||
| EPS Diluted | 3,077.78% | 41.94% | |||
| Normalized Diluted EPS | 73.33% | 77.27% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||